CEN

"Outside the top flight, Cenes Pharmaceuticals surged 20½ to 52½p after revealing it is in discussions about a possible bid for the biotechnology company. Shares in Cenes have crashed almost 90pc in the past 12 months, as the group has been searching for a year for a partner for M6G, its lead product which is a morphine alternative for post-operative pain."

http://www.telegraph.co.uk/money/main.jhtml?xml=/money/2008/02/06/cxmktrep106.xml